PRLD
Companies
NASDAQ
Prelude Therapeutics Inc.
Health Care
$0.86
-$0.41 (-32.55%)
Price Chart
Overview
About PRLD
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Market Cap
$206.0M
Volume
102.8K
Avg. Volume
115.5K
P/E Ratio
-0.5849007
Dividend Yield
0.00%
Employees
127.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.15
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, PRLD shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$206.0M
Volume102.8K
P/E Ratio-0.58
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 7, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025